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Abstract: Skin pigmentary abnormalities are seen as aesthetically unfavorable and have 
led to the development of cosmetic and therapeutic treatment modalities of varying 
efficacy. Hence, several putative depigmenting agents aimed at modulating skin 
pigmentation are currently being researched or sold in commercially available products. In 
this review we will discuss the regulation of processes that control skin complexion 
coloration. This includes direct inhibition of tyrosinase and related melanogenic enzymes, 
regulation of melanocyte homeostasis, alteration of constitutive and facultative 
pigmentation and down-regulation of melanosome transfer to the keratinocytes. These 
various processes, in the complex mechanism of skin pigmentation, can be regulated 
individually or concomitantly to alter complexion coloration and thus ameliorate skin 
complexion diseases.  
 
Keywords: depigmenting agents; hyperpigmentation; melanin; pigment; tyrosinase 
 
  
OPEN ACCESSInt. J. Mol. Sci. 2009, 10      
     
4067
1. Introduction  
 
The acquisition of an aesthetically pleasing skin pigmentary appearance has been a primary focus of 
many cosmetic and therapeutic based industries. As a result, several treatment modalities are being 
investigated for their efficacy in treating skin hyperpigmentary lesions. This review will detail many of 
the current skin depigmenting agents and treatment approaches that are currently being employed to 
combat skin pigmentary disorders.  
Scheme 1. Process of melanogenesis within epidermal melanosomes. 
 
Tyrosinase, the rate limiting enzyme of melanogenesis, catalyzes the hydroxylation of L-tyrosine to 
DOPA and the oxidation of DOPA to DOPAquinone. If cysteine or glutathione is present, it reacts 
with DOPAquinone to produce cysteinylDOPA and the benzothiazine derivatives of pheomelanin. 
As cysteine is diminished, DOPAquinone cyclizes into DOPAchrome. TYRP-2 catalyzes the 
tautomerization of DOPAchrome to 5,6-dihydroxyindole-2-carboxylic acid (DHICA), which is 
later oxidized to DHICA-melanin subunits. The oxidation of DHICA to eumelanin is thought to be 
catalyzed by TYRP-1. In the absence of TYRP-2 the carboxylic acid moiety of DOPAchrome is 
spontaneously lost to form 5,6-dihydroxyindole (DHI). DHICA in conjunction with DHI comprise 
subunits of eumelanin [11,12]. 
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Melanocytes, the pigment producing cells of the follicular and interfollicular epidermis, produce a 
specialized lysosomal related organelle termed the melanosome. Within the melanosome, biopolymers 
of the pigment melanin are synthesized to give hair and skin, as well as other tissue, its color. This 
melanin synthesis involves a bipartite process in which structural proteins are exported from the 
endoplasmic reticulum and fuse with melanosome-specific regulatory glycoproteins released in coated 
vesicles from the Golgi-apparatus. Melanin synthesis ensues subsequent to the sorting and trafficking 
of these proteins to the melanosome [1,2]. Each melanocyte resides in the basal epithelial layer and, by 
virtue of its dendrites, interacts with approximately 36 keratinocytes to transfer melanosomes and 
protect the skin from photo-induced carcinogenesis. Furthermore, the amount and type of melanin 
produced and transferred to the keratinocytes with subsequent incorporation, aggregation and 
degradation influences skin complexion coloration [3]. Hyperpigmentary disorders of the skin such as 
melasma, agespots or solar lentigo can result from the overproduction and accumulation of melanin 
[4,5]. As such, depigmenting agents can have potent effects by acting on one or more steps in the 
melanogenic pathway, melanosome transfer or post-transfer pigment processing and degradation. 
Tyrosinase, the rate limiting enzyme of the melanogenic pathway, is a copper containing 
glycoprotein of approximately 60-70 kDa and a common target for therapeutic agents intended to 
alleviate cutaneous hyperpigmentation [6,7]. The biosynthesis of the two major forms of melanin, 
black/brown eumelanin and yellow/red pheomelanin is initially catalyzed by tyrosinase. Specifically, 
the enzyme catalyzes the hydroxylation of the monophenol L-tyrosine to the o-diphenol  
3,4-dihydroxyphenylalanine (DOPA) and the oxidation of DOPA to the o-quinone DOPAquinone 
(Scheme 1) [8,9]. Several depigmenting agents modulate skin pigmentation by influencing the 
transcription and activity of tyrosinase as well as related melanogenic enzymes tyrosinase related 
protein-1 (TYRP-1), tyrosinase related protein-2 (TYRP-2) and/or peroxidase [10]. 
 
2. Transcriptional Regulation of Melanogenic Enzymes 
 
The transcriptional level is the first stage by which the expression of tyrosinase and related 
melanogenic enzymes may be modulated. Influential in this process, the microphthalmia-associated 
transcription factor (MITF) is a basic helix-loop-helix leucine zipper transcription factor that regulates 
melanocyte cellular differentiation as well as the transcription of melanogenic enzymes (tyrosinase, 
TYRP1 and TYRP2) and melanosome structural proteins (MART-1 and PMEL17) [13-15]. Mutations 
in the MITF gene are associated with auditory and pigmentary abnormalities of Waardenburg 
syndrome type IIA [16,17].  
The MITF-M isoform, with the promoter most proximally located upstream to the common exon 
sequences, is exclusively expressed in melanocytes and is believed to bind the M box regulatory 
element and transactivate the promoter of tyrosinase, TYRP-1 and TYRP-2, as well as other genes. 
[7,10,13,15,18,19]. It is believed that upon stimulatory binding of α-melanocyte stimulating hormone 
(α-MSH) to the melanocortin 1 receptor (MC1R), adenyl cyclase is activated and cAMP produced. 
cAMP then activates the protein kinase A (PKA) pathway to phosphorylate cAMP-responsive element 
binding protein (CREB) transcription factors, which mediates MITF-M promoter activation to induce 
melanogenesis. MITF is also regulated at the transcriptional level by interleukin-6 (IL-6) and Wnt 
Signaling pathway. Furthermore, MITF is post-transcriptionally regulated by phosphorylation via Int. J. Mol. Sci. 2009, 10      
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ribosomal S6 kinase (RSK), glycogen synthase kinase-3b (GSK3b), p38 stress signaling and   
mitogen-activated protein kinase (MAPK) pathways by currently undefined mechanisms/pathways 
[15,18,20,21]. As MITF is considered an important regulator of melanogenesis, manipulation of the 
aforementioned signaling pathways may have potential therapeutic use.  
Transforming growth factor-β1 (TGF-β1) is a cytokine that plays a role in cell differentiation, 
proliferation and apoptosis, in addition to the inhibition of pigmentation. TGF-β1 is believed to 
mediate the down-regulation of the MITF promoter activity, reducing the production of tyrosinase, 
TYRP-1, TYRP-2 and MITF protein levels [20,22]. Yang et al. have shown that TGF-β1 inhibits the 
expression of paired-box homeotic gene (PAX 3), a transcription factor and key regulator of MITF in 
melanocytes [23]. Kim et al. have also demonstrated that TGF-β1 influences the extracellular-signal 
related kinase (ERK) pathway and down-regulates MITF as well as melanogenic enzyme production 
[20,22,24,25]. Similarly, ERK activation by sphingosine-1-phosphate, C2-ceramide and 
sphingosylphosphorylcholine has also been reported by Kim et al., which the authors hypothesize, may 
play an important role in the inhibition of melanogenesis [25-27]. ERK activation, in those cases, is 
thought to result in phosphorylation of MITF and its subsequent ubiquitination and degradation   
[25,28-30]. In a distinct study, the authors demonstrated that lysophosphatidic acid (LPA), a serum 
phospholipid released by activated platelets, mediates the reduction of MITF promoter activity as well 
as MITF and tyrosinase protein and melanin synthesis in Mel-Ab cells, an immortalized mouse 
melanocyte line [31].  
In addition to the process of melanization, MITF also regulates melanocyte differentiation, 
development, and survival [32]. Pertaining to survival, MITF regulates the anti-apoptotic molecule 
Bcl-2 as well as additional survival genes [33,34]. It has recently been demonstrated that melanocytes 
deficient in MITF expression are compromised in their resistance to UV-induced apoptosis [35]. 
Therefore, caution is warranted when attempting to decrease skin pigmentation by down-regulating 
MITF since melanocyte death may be a consequence.  
 
3. Post-Translational Modification of Melanogenic Enzymes  
 
A major post-translational modification of melanogenic enzymes is the attachment of N-linked 
glycans to asparagine residues in Asn-X-Ser/Thr motifs (where X is not Pro), during the polypeptides 
translocation in the ER. This glycosylation is critical for the proper maturation of tyrosinase 
[10,36,37]. A detailed review of the processes involved in the N-glycosylation of melanogenic 
enzymes has been published by Branza-Nichita et al. [37]. Inhibition of proper N-glycan processing of 
melanogenic enzymes can result in improper polypeptide folding and in turn inhibition of 
melanogenesis, as they facilitate association with lectin-chaperones. Treatment with various agents 
that inhibit N-glycosylation can result in the down-regulation of melanosomal enzyme activity and 
reduced melanosomal maturation [9,10,37,38]. 
Studies completed by Mishima and Imokawa using tunicamycin and glucosamine, specific 
inhibitors of lipid carrier-dependent glycosylation of protein, resulted in decreased pigmentation and 
ultrastructural as well as biochemical aberrations in melanogenic compartments of treated B16 
melanoma cells. In addition, electron microscopic analysis showed melanosomes with internal 
structural irregularities and pigment loss [10,39]. In a more recent study, Terao et al. tested a novel Int. J. Mol. Sci. 2009, 10      
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compound, BMY-28565, that inhibited melanogenesis by depressing tyrosinase activity with no 
impact on tyrosinase mRNA levels in B16 melanoma cells. As other active derivatives of the 
compound cause an increase in protein glycosylation in B16 melanoma cells, the authors hypothesize 
that the test compound inhibited tyrosinase by modifying the sugar moieties of the enzyme [40,41]. In 
a distinct study by Choi et al., treatment of HM3KO melanoma cells with deoxynojirimycin, a   
α-glucosidase inhibitor that disrupts early ER N-glycan processing, and deoxymannojirimycin, an 
inhibitor of α-1,2-mannosidase which are thought to be responsible for late glycan processing, showed 
inhibition of glycosylation, transportation of tyrosinase to the melanosome and melanin synthesis [42]. 
Other factors explored for their ability to modulate tyrosinase glycosylation include calcium   
D-pantetheine-S-sulfonate [43], ferritin [44] and glutathione [45]. Glutathione induced inhibition of 
tyrosinase glycosylation, blocks the maturation and transfer of tyrosinase from GERL   
(Golgi-endoplasmic reticulum-lysosome)-coated vesicles to the pre-melanosome. Yet, other 
mechanisms of action proposed for glutathione include (A) the direct inactivation of tyrosinase by 
chelating copper within the enzyme’s active site, (B) mediating the transition from eumelanogenesis to 
pheomelanogenesis, as glutathione participates in the conversion of dopaquinone to pheomelanin,   
(C) antioxidant properties that quench free radicals and peroxides that induce melanin formation and 
(D) modulating the depigmenting capabilities of melanocytotoxic agents [20,46].  
 
4. Attenuation of Tyrosinase and Related Melanogenic Enzymes Catalytic Activity 
 
4.1. Hydroquinone 
 
Hydroquinone (1,4-dihydroxybenzene, HQ) has been the gold standard for treating 
hyperpigmentation for more than 50 years and has been successfully used to treat melanosis. The 
compound can be found in wheat, tea, berries, beer and coffee, but is detoxified within the liver into 
inert compounds [6,47]. Hydroquinone is a phenolic compound and depigmenting agent that mainly 
exerts its effect on melanocytes with active tyrosinase. As HQ dependent melanogenic inhibition 
requires the presence of active tyrosinase, it is therefore not useful in altering the color of melanin that 
is previously present in the dermis and epidermis [48].  
The structural similarity between HQ and melanogenic precursors enables HQ’s interaction with 
tyrosinase. This interaction mediates HQ’s inhibition of tyrosinase by binding histidines or copper at 
the active site of the enzyme. Additionally, HQ induced generation of reactive oxygen species and 
quinones leads to the oxidative damage of membrane lipids and proteins such as tyrosinase. 
Hydroquinone is also thought to inhibit pigmentation by depleting glutathione, modifying melanosome 
formation or reducing DNA and RNA synthesis with concomitant melanosome degradation and 
melanocyte destruction [10,20,49,50].  
Traditional hydroquinone formulations contain other constituents that promote a synergistic effect. 
A popular formulation is comprised of hydroquinone and a corticosteroid to reduce inflammation, 
along with tretinoin, shown to reduce the atrophy associated with the corticosteroid and remove 
pigmentation by increasing keratinocyte turnover and the penetration of hydroquinone [50,51].  
Due to the risks of side effects such as exogenous ochronosis and permanent depigmentation 
following long term use, hydroquinone has been banned by the European Committee (24
th Dir Int. J. Mol. Sci. 2009, 10      
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2000/6/EC) and formulations have been withdrawn from cosmetics and are available only through 
prescription [10,20,50].  
Other phenolic compounds have been evaluated for their depigmenting capabilities. In fact the 
chemical structures of several phenolic compounds have been investigated to delineate structure 
related tyrosinase inhibitory activity. It has been suggested that having a hydroxyl group para to an 
electron donator group is required for a compound to be an effective alternative substrate for 
tyrosinase [10]. Distinct structure-activity based analysis done by Ni-Komatsu et al. on quinolines, 
which contain a 4-substituted amino group with a tertiary amine side chain, shows significant 
inhibitory effect. Yet these quinolines, such as chloroquine, were not reported to influence the 
enzymatic activity of tyrosinase, but rather the intracellular trafficking of tyrosinase related proteins 
and lysosome associated membrane protein-1 (LAMP-1) [52]. 
 
4.2. Monobenzylether  
 
The mono benzyl ether of hydroquinone (MBEH) is a related compound that is metabolized within 
the cell to form a quinone species that interacts with and results in permanent depigmentation, even at 
areas distant from the site of application. MBEH can destroy melanocytes and should not be used to 
treat post-inflammatory hyperpigmentation or melasma. MBEH therapy is appropriate for generalized 
depigmentation in the treatment of patients with vitiligo unresponsive to repigmentation therapy 
[10,20,48]. Proposed mechanisms of action for MBEH are both cytotoxicity to melanocytes as a result 
of free radical formation and competitive inhibition of tyrosinase activity [6].  
 
4.3. Arbutin and Deoxyarbutin 
 
Arbutin (hydroquinone-O-β-D-glucopyranoside), a derivative of hydroquinone, is a botanically 
derived compound found in cranberries, blueberries, wheat and pears [6,51]. Arbutin is used as an 
effective treatment of hyperpigmentary disorders, and displays less melanocyte cytotoxicity than 
hydroquinone. The compound inhibits melanogenesis by competitively and reversibly binding 
tyrosinase without influencing the mRNA transcription of tyrosinase. It also inhibits the maturation of 
melanosomes, possibly by its reported influence on DHICA polymerase activity and Pmel-17 protein. 
The mild effect of arbutin is attributed to the controlled release of hydroquinone as a result of in-vivo 
cleavage of the glycosidic bond. Higher concentrations of arbutin are more efficacious than lower 
concentrations, but may cause paradoxical hyperpigmentation [20,45,49,51,53]. Deoxyarbutin (dA), a 
synthetic form of arbutin synthesized without the hydroxyl moiety, provides a promising treatment for 
reducing skin hyperpigmentation [50]. dA shows reversible inhibition of tyrosinase activity with 
associated skin lightening in both a hairless guinea pig model system and in human skin. The 
reversibility of dA’s impact on skin pigmentation suggests that the compound does not permanently 
destroy melanocytes [20,54,55]. In addition to the reported efficacy, Hamed et al. have found that dA 
is less cytotoxic/cytostatic than HQ in treatment of cultured human melanocytes [56]. Chawla et al. 
have reported that dA and associated second-generation derivatives, dose-dependently inhibit 
tyrosinase hydroxylation and DOPAoxidase activity of tyrosinase. This may be attributed to the Int. J. Mol. Sci. 2009, 10      
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chemical structure of dA, as the deoxysugars may increase skin penetration and binding affinity for 
tyrosinase [20,54].  
 
4.4. Mequinol 
 
Mequinol (hydroquinone monomethyl ether, 4-hydroxyanisole, para-hydroxymethoxybenzene), 
another derivative of hydroquinone, is enzymatically oxidized by tyrosinase to produce 
melanocytotoxic quinones. The formation of quinones results in pigment cell destruction and skin 
depigmentation [10,57]. The combination of 0.01% tretinoin with mequinol has been reported to 
inhibit melanin production and has been shown to be effective and safe in the treatment of solar 
lentigenes and related hyperpigmentation [48,50,58,59]. 
 
4.5. N-Acetyl-4-S-Cysteaminylphenol  
 
N-Acetyl-4-S-cysteaminylphenol (NCAP) is a phenolic thioether that has been used in the treatment 
of epidermal hyperpigmentation such as melasma and also in anti-melanoma studies. NCAP is 
structurally similar to tyrosine and acts specifically in melanin-synthesizing cells as an alternative 
tyrosinase substrate [48,50,60]. Ferguson et al. suggests that NCAP may undergo oxidation by 
tyrosinase to form a reactive o-quinone that is capable of alkylating thiol groups of essential enzymes, 
which may interfere with cell growth and proliferation [61]. In a 12 patient study of the efficacy of 
NCAP completed by Jimbow, the author describes an 8% complete loss and 66% marked 
improvement in visible changes of melanoderma after 2 to 4 weeks of topical application. The author 
attributes this depigmentation to a decrease in the number of functional melanocytes and the number of 
melanosomes transferred to keratinocytes. NCAP is suggested to be a depigmenting agent that is less 
irritating and more stable than HQ, with specificity for melanin-synthesizing cells [60]. 
 
4.6. Kojic Acid 
 
Kojic acid (5-hydroxy-2-hydroxymethyl-4H-pyran-4-one, KA) is a naturally occurring hydrophilic 
fungal metabolite obtained from species of Acetobacter, Aspergillus and Penicillium [48,49]. Kojic 
acid is believed to inactivate tyrosinase by chelating copper atoms as well as suppressing the 
tautomerization of dopachrome to DHICA. [50] Although KA is a popular treatment for melasma, it is 
associated with sensitization, contact dermatitis and erythema [51]. A distinct, more stable derivative 
of kojic acid synthesized by Kim et al., 5-[(3-aminopropyl)phosphinooxy]-2-(hydroxymethyl)-4H-
pyran-4-one (Kojyl-APPA), showed increased skin penetration and pigment lightening efficacy in 
melanoma and normal human melanocytes [20,62].  
 
4.7. Azelaic Acid 
 
Azelaic acid (1,7-heptanedicarboxyilic acid, AZA) is a naturally occurring non-toxic straight chain, 
saturated dicarboxylic acid derived from Pityrosporum ovale [57,63,64]. AZA appears to selectively 
influence the mechanism of hyperactive and abnormal melanocytes, but minimally influences normal Int. J. Mol. Sci. 2009, 10      
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skin pigmentation, freckles, nevi and senile lentigenes [6,10,65]. AZA’s antiproliferative and cytotoxic 
effect may be mediated by the inhibition of DNA synthesis and mitochondrial oxidoreductase activity. 
The compound is also able to bind amino and carboxyl groups and may prevent the interaction of 
tyrosine in the active site of tyrosinase and thus function as a competitive inhibitor. Although not all 
authors are in agreement with the therapeutic efficacy of AZA, it has been reported to be effective in 
treatment of melasma and acne [10,65]. A 24 week multicenter, controlled, double blind clinical trial 
of 329 women completed by Baliña et al. compared the efficacy of a 20% AZA cream to a 4% HQ 
cream in treating melasma. The authors reported no significant difference between the results where 
~65% of the patients treated with AZA were reported to achieve good to excellent results compared to 
~73% of HQ treated patients [66]. 20% azelaic acid seems to be well tolerated in treated patients with 
no systemic side effects, but some local cutaneous irritation, a burning sensation, mild erythema, 
scaling and pruritus that subsided 2 to 4 weeks post treatment [65,67]. 
 
4.8. Gentisic Acid 
 
The methyl ester of gentisic acid (2,5-dihydroxybenzoic acid, MG) is a natural derivative of 
Gentianas root with the capacity to inhibit tyrosinase. MG can act as a pro-drug that releases HQ 
which subsequently inhibits tyrosinase. Yet, methyl gentisate is less cytotoxic and mutagenic than  
HQ [10,20,50]. 
 
4.9. Flavonoid-like Agents  
 
Flavonoids are natural plant polyphenols found in leaves, bark and flowers. Some 4,000 members 
have been identified to date, all benzo-γ-pyran derivates comprised of phenolic and pyran rings. These 
polyphenolic compounds are known to have anti-inflammatory, antiviral, antioxidant and 
anticarcinogenic properties [20,50,63]. The flavonoids may also have ROS scavenging properties and 
the ability to chelate metals at the active site of metalloenzymes. Flavonoids may have 
hypopigmenting capabilities by directly inhibiting tyrosinase activity at distal portions of the 
melanogenic pathway [20]. Structure-function analysis of flavonoids suggests that flavonoids with an 
α-keto group show potent tyrosinase inhibition due to the similarity between the dihydroxyphenyl 
group of DOPA and the α-keto containing flavonoids [63]. Similar analysis completed by Kubo et al. 
suggests that flavonoids have the capability to chelate copper in tyrosinase’s active site as long as the 
3-hydroxygroup is free [64,68]. A comprehensive review on the properties of plant polyphenols has 
been published by Kim et al. [63] Flavonoids that will be reviewed here include aloesin, 
hydroxystilbene derivates and licorice extracts.  
 
4.9.1. Aloesin 
 
Aloesin is a natural hydroxymethyl chromone compound derived from aloe vera plants [49]. It 
competitively inhibits the function of tyrosinase by inhibiting the hydroxylation of tyrosine to DOPA 
and oxidation of DOPA to dopaquinone [50]. Studies completed by Jones et al. on normal human 
melanocytes treated with aloesin, showed a dose dependent decrease in tyrosinase activity [69]. The Int. J. Mol. Sci. 2009, 10      
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hydrophilic nature of the compound reduces the skin penetration of aloesin. Hence, combination 
treatment of aloesin with arbutin has been studied to assess the synergistic effects on tyrosinase 
activity. The two adhere to different mechanisms of action where aloesin exhibits noncompetitive 
inhibition while arbutin inhibits competitively [49,64,69-71]. Testing of aloesin revealed no 
cytotoxicity, which makes it a good alternative to HQ [50]. 
 
4.9.2. Hydroxystilbene  
 
Some of the more efficient pigment lightening flavonoid subcategories are the hydroxystilbene 
compounds, derived from natural products found in oriental herbal medicines. There are more than 30 
stilbene and stilbene glycosides with a structural skeleton comprised of two aromatic rings linked by 
an ethylene bridge [20,72]. Commonly studied hydroxystilbene products include resveratrol   
(3,4’,5 trihydroxystilbene), its isomer oxyresveratrol and methoxylated or glycosylated analogs   
piceid-glucoside, rhapontigenin and rhaponticin [20,73]. The number and position of hydroxyl 
substituents of hydroxystilbene compounds seem to play an important role on the inhibition of 
tyrosinase activity [74]. However, glycosylated hydroxystilbene compounds such as piceid, the 
glycoside of resveratrol at position 3, exhibit decreased tyrosinase inhibition compared to the parent 
compound [72]. In all cases, tyrosinase inhibition is reversible and in turn requires a high 
concentration of hydroxylated stilbenes within melanocytes [20]. Resveratrol, a commonly studied 
hydroxystilbene, is found in red wine and displays free radical scavenging, anticancer and   
anti-inflammatory activities [10]. Some data attribute resveratrol depigmenting affect to its ability to 
reduce Mitf and tyrosinase promoter activities in B16 mouse melanoma cells [18,20]. However, other 
contradictory results suggest that resveratrol treated normal human melanocytes (NHM) display 
steady-state tyrosinase RNA and, as such, regulation of tyrosinase transcription does not influence its 
depigmentation [75]. Additionally, further analysis of the resveratrol treated NHM displayed   
ER-retained immature tyrosinase, suggesting disrupted trafficking of tyrosinase in the GERL and 
elevated proteolytic degradation [75]. The resveratrol analog oxyresveratrol is a stronger inhibitor than 
resveratrol. Oxyresveratrol has been described to have a potent dose-dependent non-competitive 
inhibition on L-tyrosine oxidation by tyrosinase from mushroom and murine melanoma B-16, without 
suppression of tyrosinase synthesis or expression [74]. The hydroxystilbene products still require more 
analysis to properly elucidate their pigment lightening effect and mechanism(s) of action.  
 
4.9.3. Licorice Extract 
 
Licorice extract is obtained from the root of Glycyrrhia Glabra Linneva and has been used in 
traditional Chinese medicine [6,20,48]. The main component of the hydrophobic fraction of licorice is 
glabridin. Glabridin has been shown to prevent UVB-induced pigmentation and to inhibit tyrosinase 
activity, superoxide anion production and cyclo-oxygenase activity. This suggests an influence of 
glabridin extract on both melanogenesis and inflammation of the skin [48,50]. Other active agents of 
licorice extracts include liquiritin and isoliquertin. Liquiritin is a glycoside containing flavonoid that 
induces skin lightening by dispersing melanin [49]. Licorice extracts also influence pigmentation by 
removing epidermal melanin, inhibiting the biosynthesis of melanin and inhibiting the activity of Int. J. Mol. Sci. 2009, 10      
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tyrosinase in a dose-dependent manner. Licorice extract has been tested in the treatment of melasma 
with good results and very mild irritation [50,51]. 
 
4.10. Antioxidants and Redox Agents  
 
Ultraviolet radiation influences the proliferation of melanocytes and the production and secretion of 
paracrine and autocrine factors that stimulate melanogenesis. UV radiation can also produce reactive 
oxygen species (ROS) in the skin that may induce melanogenesis, DNA damage, melanocyte 
proliferation and/or apoptosis [76,77]. The skin contains a number of antioxidants that can be depleted 
by UV exposure and cause oxidative damage. The application of topical antioxidants has the capacity 
to prevent oxidative damage to the skin [78]. Redox agents capable of scavenging ROS generated in 
the skin can inhibit second messengers that may stimulate melanogenesis. Redox agents can also 
influence skin pigmentation by interacting with copper at the active site of tyrosinase or with   
o-quinones to impede the oxidative polymerization of melanin intermediates [10,79]. Here we will 
review vitamin C, vitamin E and later we will review the vitamin B derivative niacinamide.  
 
4.10.1. L-Ascorbic Acid and Magnesium-L-Ascorbyl-2-Phosphate 
 
L-Ascorbic Acid (vitamin C, AsA), obtained from citrus fruits and leafy green vegetables, is a water 
soluble vitamin and the most plentiful antioxidant in human skin [51,80]. AsA interferes with melanin 
synthesis by reducing oxidized dopaquinone, interrupting DHICA oxidation and interacting with 
copper ions at the active site of tyrosinase. AsA acts as an ROS scavenger by donating electrons to 
neutralize free radicals found in the aqueous compartment of the cell [10,80]. Unfortunately, AsA is 
highly unstable and is rapidly oxidized and decomposed in aqueous solutions. The hydrophilic nature 
of AsA also limits its skin penetration, unless the stratum corneum barrier is disrupted [10,51]. The 
more stable ascorbate ester, magnesium-L-ascorbyl-2-phosphate (MAP) is more lipophilic and has a 
greater permeation through the stratum corneum [50,51]. MAP is then hydrolyzed by phosphatases in 
the skin to AsA and demonstrates the reducing capabilities of AsA [81]. In related skin lightening 
studies, Hakozaki et al. have used ultrasound to increase the transepidermal penetration and efficacy of 
the vitamin C derivative, ascorbyl glucoside and niacinamide [82]. 
 
4.10.2. Alpha Tocopherol and Alpha Tocopherol Ferulate 
 
Vitamin E (α-tocopherol,  α-Toc) is a lipophilic antioxidant in the body, derived from cereal, 
vegetables, vegetable oil and nuts [51]. α-Toc is known to inhibit the oxidative attack of free and 
membrane bound unsaturated fatty acid and interferes with the lipid peroxidation of melanocyte 
membranes. The vitamin is also able to scavenge free radicals including superoxide anions, hydroxyl 
radicals and singlet molecular oxygen. It can also act as a humectant. The depigmenting effect of  
α-Toc can further be attributed to an increase in intracellular glutathione and the inhibition of 
tyrosinase [51,83-85]. α-Tocopherol ferulate (α-TF) is a related compound, in which α-tocopherol is 
linked by an ester bond to ferulic acid, an antioxidant that stabilizes α-Toc [10]. The presence of 
another antioxidant ferulic acid, causes a rapid regeneration of α-Toc and maintains a long lasting Int. J. Mol. Sci. 2009, 10      
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antioxidant effect. A study completed investigating the biochemical effect of α-TF in human 
melanoma cells suggests the whitening effect is due to tyrosinase inhibition at the post-transcriptional 
level, possibly by an unidentified secondary molecule [50,86]. 
 
5. Interruption of Melanosome Transfer 
 
Regulation of cutaneous pigmentation is dependent on several processes beyond melanin synthesis 
within the melanosome. The efficiency of melanosomal transfer from melanocytes to keratinocytes, 
followed by melanosome processing in the recipient keratinocytes plays a critical role in skin 
pigmentation. Without successful transfer of melanosomes to keratinocytes, the skin can appear 
essentially unpigmented [87]. Treatment modalities aimed at inhibiting melanosome transfer may 
influence and modulate skin pigmentation. 
 
5.1. Centaureidin and Methylophiopogonanone B 
 
The first step of melanosome transfer from melanocytes to surrounding keratinocytes is successful 
melanocytic dendrite formation and extension towards surrounding keratinocytes. The extension of 
melanocytic dendrites requires the reorganization of the melanocyte cytoskeletal elements such as 
actin filaments and microtubules [88]. Small GTPases Rho, Rac and Cdc42 play a pivotal role in cell 
morphology and dendrite formation. Specifically, Rac stimulates membrane ruffling and lamellipodia 
formation, Rho activates dendrite retraction and Cdc42 mediates filopodia and peripheral actin 
microspike formation [88-90]. Ito et al. has shown that treatment of melanocyte and keratinocyte co-
cultures with methylophiopogonanone B (5,7-dihydroxy-6,8-dimethyl-3-(4-methoxybenzyl)chroman-
4-one, MOPB), an agent reported to activate Rho and induce microtubule disorganization and tubule 
depolymerization, appeared to reduce melanosome transfer [89,90]. The authors also showed that 
treatment with 1µM MOPB did not influence melanin synthesis or the expression of melanogenic 
enzymes. MOPB appeared to induce a reversible dendrite retraction and transfer inhibition without 
associated cytotoxicity (tested up to 72 hours) [89]. Centaureidin (5,7,3’-trihydroxy-3,6,4’-
trimethoxyflavone), a flavonoid glucoside derived from yarrow, also reduces melanosomal transfer to 
keratinocytes. Centaureidin is believed to directly or indirectly activate Rho, leading to melanocyte 
dendrite retraction without influencing melanogenic enzyme expression or melanin synthesis [88,91]. 
More analysis is needed to confirm the applicability of MOPB and centaureidin as skin   
lightening agents. 
 
5.2. Niacinamide 
 
Niacinamide (vitamin B3, nicotinamide, 3-pyridinecarboxamide) is a biologically active form of 
niacin found in many root vegetables as well as in yeast [70,92]. Physiologically, niacinamide 
functions as a precursor to the co-factors nicotinamide adenine dinucleotide (NAD) and nicotinamide 
adenine dinucleotide phosphate (NADP). Along with their reduced forms NADH and NADPH, these 
enzymes participate in numerous enzymatic reactions and also act as antioxidants [70,92]. 
Niacinamide has several proposed medicinal applications in the skin including anti-inflammation, Int. J. Mol. Sci. 2009, 10      
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prevention of photoimmunosuppression and increased intercellular lipid synthesis [93]. Niacinamide’s 
role as a co-enzyme precursor may explain the multiple roles it has in skin, but this is not clearly 
defined [82,94]. Topical niacinamide is described to have several benefits on aging skin including but 
not limited to improved barrier function, improved appearance of photoaged facial skin (including 
texture, hyperpigmentation, redness, fine lines and wrinkles) and reduced sebum production   
[92,94-97]. Additionally, niacinamide is believed to influence cutaneous pigmentation by   
down-regulating transfer of melanosomes from the melanocytes to the keratinocytes [20,57,92]. 
Studies completed by Hakozaki et al. suggest that niacinamide has no effect on tyrosinase activity, 
melanin synthesis or melanocyte number in a monolayer culture system. Alternatively, the authors 
found that niacinamide down-regulated the number of melanosomes transferred from melanocytes to 
keratinocytes by 35 to 68% in a co-culture model system [92]. The actual process by which 
niacinamide down-regulates melanosome transfer remains to be properly established.  
 
5.3. PAR-2 Inhibitors 
 
PAR-2 belongs to a family of transmembrane G-protein coupled receptors (PAR1-PAR4) that are 
proteolytically activated by serine proteases. Specifically, the serine proteases (including trypsin or 
mast cell tryptase) cleave the extracellular amino terminal domain exposing a newly created   
N-terminus tethered ligand that undergoes a conformational change, binds and subsequently activates 
the receptors [98,99]. Within the epidermis, PAR-2 is expressed in keratinocytes, but not in 
melanocytes and is involved in the regulation of skin pigmentation through melanocyte-keratinocyte 
interactions [99-103]. Studies completed on keratinocyte PAR-2 indicate that it may influence 
melanosome incorporation and phagocytosis by keratinocytes and play a regulatory role in skin 
pigmentation. Therefore, modulation of PAR-2 activity augments or decreases melanosome transfer 
and in turn skin pigmentation [99,103-106]. PAR-2 activation can be achieved by synthetic peptides 
corresponding to the sequence of the N-terminal ligand. The peptide of mouse PAR-2 cleavage 
sequence SLIGRL is an equipotent activator of mouse and human PAR-2 receptor in comparison to 
the human tethered ligand SLIGKV [100]. Interestingly, PAR-2 expression and induction by 
ultraviolet irradiation is dependent on skin type, with a higher overall expression and induction in 
darker skin individuals [98,104,107]. Activation of PAR-2 enhances melanosome transfer, while 
inhibition of PAR-2 by serine protease inhibitors can result in reduced melanosomal transfer and 
distribution. Work published by Seiberg et al. and Paine et al. has shown that this inhibition leads to a 
dose-dependent lightening of skin pigmentation [103,104,106]. Work completed by Seiberg et al. 
examining the effect of serine protease inhibitor RWJ-50353 on epidermal equivalents shows an 
accumulation of melanosomes in melanocytes, with an increase in early stage melanosomes compared 
to untreated controls. They hypothesize that the keratinocytes inability to receive the presented 
melanosomes leads to an accumulation of melanosomes in the melanocytic dendrite and a concomitant 
negative feedback mechanism that slows pigment production. The authors additionally showed that 
Yucatan swine skin treated with RWJ-50353 for an 8 week period demonstrated a dose dependent, 
reversible skin lightening effect [103]. 
“Natural” therapies derived from soybeans have been explored for their safety and efficacy as 
depigmentation treatments. Two protein proteinase inhibitors have been isolated from soybean seeds Int. J. Mol. Sci. 2009, 10      
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Kunitz-type trypsin inhibitor (soybean trypsin inhibitor, STI) and the Bowman-Birk protease inhibitor 
(BBI). STI and BBI are found in the seeds of soybeans, but not in the other regions of the plant. STI 
inhibits trypsin proteolysis by forming a stable stoichiometric complex and BBI inhibits trypsin and 
chymotrypsin at separate reactive sites [106,108]. Work completed by Paine et al. has shown that 
soymilk and soybean extract reduces pigmentation in dark skinned Yucatan swine treated for an   
eight week period. The authors suggest that the soymilk inhibits PAR-2 activation in the skin and 
results in skin depigmentation. Moreover, the authors suggest that STI and BBI inhibit PAR-2 
activation, causes a reduction in keratinocyte phagocytosis and a reduction in resulting skin 
pigmentation [106]. Soymilk also contains other constituents that may induce skin lightening such as 
trace amounts of free fatty acids and their acyl CoA esters that can inhibit trypsin and may participate 
in PAR-2 inhibition. Soybeans contain isoflavones, which are antioxidants that may reduce 
tyrosinase’s DOPA oxidase activity. In addition, soybeans contain phospholipids which the authors 
suggest may assist in the epidermal delivery of STI and BBI without the assistance of liposomes, when 
soy milk is used as a topical treatment [51,106]. 
 
5.4. Lectins and Neoglycoproteins 
 
Cellular recognition between melanocytes and keratinocytes is an important event involved in 
melanosome transfer [87]. Lectins and neoglycoproteins have been explored as candidates that are 
involved in this phenomenon, because of their influence in cellular processes including intracellular 
trafficking, endocytosis and cell-cell recognition [87,93]. Interestingly, Minwalla et al. have 
demonstrated a role for melanocyte and keratinocyte membrane glycosylated residues in the process of 
receptor-mediated endocytosis to facilitate melanosome transfer. The authors suggest that lectins and 
neoglycoproteins play an inhibitory role in this process [20,87]. Specifically, plasma membrane lectins 
and their glycoconjugates are thought to interrupt melanocyte and keratinocyte contact and interaction, 
by binding their specific plasma membrane receptors, inhibiting melanosome transfer [109]. This 
inhibition is reversible and is shown to be enhanced by the presence of niacinamide [93]. 
 
6. Acceleration of Epidermal Turnover and Desquamation  
 
The capability of a compound to accelerate the turnover of epidermal layers and/or disperse 
melanin pigment can result in skin lightening. Chemical agents used to exfoliate the skin, stimulates 
the removal of pigmented upper layer keratinocytes to lighten skin [10,110].  
 
6.1. α-Hydroxyacids  
 
α-Hydroxyacids (AHA) are weak organic acids found in fruits, plants and milk sugars [111]. For 
centuries, α-hydroxyacids have been one of the most commonly utilized peeling agents used to treat 
dry skin, acne, actinic damage and to improve skin color/texture [51]. AHAs are also reported to 
effectively treat pigmentary lesions such as solar lentigenes, melasma and post inflammatory 
hyperpigmentation (PIH). At low concentrations AHAs promotes exfoliation by decreasing corneocyte 
cohesion and stimulating new growth in the basal layer, while at higher concentrations AHAs promote Int. J. Mol. Sci. 2009, 10      
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epidermolysis and dispersed basal layer melanin. The accelerated desquamation of the stratum 
corneum by AHAs is complemented by a direct inhibition of tyrosinase, without influencing mRNA or 
protein expression [51,110,111]. Lactic acid (LA) and glycolic acid (GA) are AHAs derived from sour 
milk and sugarcane juice, respectively [110]. In a study investigating the histological differences 
between Japanese subjects treated for 6 weeks with 40% AHA, either glycolic, lactic or acetic acids, 
Yamamoto  et al. reported an increase in epidermal thickness, decreased melanin deposition and   
up-regulated collagen levels. The authors also suggest that the AHAs induced a remodeling of the 
epidermis with accelerated desquamation [112]. 
 
6.2. Salicylic Acid  
 
Salicylic Acid (SA) is a β-hydroxyacid found in willow bark and sweet birch. It is also a 
phytohormone, a plant product that acts similar to a hormone and regulates cell growth and 
differentiation. SA functions as a desquamating agent that penetrates and dissolves the intercellular 
matrix of the stratum corneum [50,111]. 
 
6.3. Linoleic Acid 
 
Unsaturated fatty acids including oleic acid (C18:1), linoleic acid (C18:2) or α-linolenic acid 
(C18:3) suppresses melanogenesis and tyrosinase activity, while saturated fatty acids such as palmitic 
acid (C16:0) or stearic acid (C18:0) increases it [113]. Linoleic acid reduces the activity of tyrosinase 
in melanocytes, while mRNA levels remain unchanged [51]. No evidence of change in TYRP-1 and 
TYRP-2 protein levels suggest that fatty acids selectively target tyrosinase. This may influence the 
enzyme’s degradation via a physiologic proteasome-dependent mechanism, altering the tyrosinase 
protein content in hyperactive melanocytes [10,114]. Linoleic acid also influences skin pigmentation 
by stimulating epidermal turnover and increased desquamation of melanin pigment from the epidermis 
[51]. Studies completed to assess the skin lightening capabilities of unsaturated fatty acids, linoleic 
acid or α-linoleic acid,  on UV induced hyperpigmentation of brown guinea pig skin, showed an 
efficient lightening effect [115]. It is thought that the unsaturated bonds of these molecules can be 
easily peroxidized, which in combination with an increase in epidermal turnover, correlate with an 
inhibitory effect on melanogenesis in vivo [51,115]. 
 
6.4. Retinoids 
 
Retinoids are a common treatment option used to ameliorate acne, photodamage and PIH. The 
mechanism of action likely involves the inhibition of tyrosinase, the dispersion of keratinocyte 
pigmented granules, reduction in pigment transfer and a reduction in corneocyte cohesion with an 
associated acceleration of epidermal turnover [20,51,116]. Tretinoin (all-trans  retinoic acid) is a 
derivative of vitamin A that is thought to have an inhibitory effect on tyrosinase transcription [117]. 
Tretinoin is reported to be effective in treating melasma, with some associated side effects including 
erythema, peeling at the site of application and PIH [20]. Tretinoin is also used in combination in 
topical creams, such as a formulation proposed by Kligman and Willis containing 5% HQ, 0.1% Int. J. Mol. Sci. 2009, 10      
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tretinoin and 0.1% dexamethasone. Tretinoin in this formulation acts as a stimulant of epidermal 
turnover and pigment reduction via epidermopoieses, an antioxidant to reduce the oxidation of HQ and 
a mild irritant to enhance the epidermal penetration of HQ [110].  
 
7. Conclusions 
 
Great advances have been made in understanding the cellular and biochemical mechanisms in 
pigment biology and the processes underlying skin pigmentation. This has led to the development of 
various skin lightening agents to reduce skin hyperpigmentation. While several agents target the rate 
limiting enzyme of melanogenesis tyrosinase, there has been an increased interest in alternative 
hypopigmenting mechanisms. Yet, as addressed by Lei et al., there is a need for a standardized and 
streamlined protocol to screen melanogenic regulatory compounds, to simplify the difficult task of 
product comparison [118]. Also, as the number of putative depigmenting agents grows there is an 
increased need for studies to clarify product efficacy, cytotoxicity, topical skin penetration, stability 
and safety. To add to the complexity, it may be more advantageous to test compounds together to 
address the synergistic effects on skin lightening, particularly when the active components influence 
distinct steps of melanogenesis [10]. While it is clear that great progress has been made in the study of 
skin lightening, it is even more apparent that there is a great deal of work still left to be done.  
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